AmritaKrishnanMD

Oncology • Irvine, CA

Hematologic Oncology

Director Multiple Myeloma Program: Professor of Medicine

Join to view full profile

Dr. Krishnan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Krishnan's full profile

Already have an account?

Office
1000 FivePoint
Irvine, CA 92618
Phone+1 949-999-8979

Fax+1 626-389-3061

Summary

Dr. Amrita Krishnan is an oncologist in Irvine, CA and is affiliated with City of Hope Comprehensive Cancer Center. She received her medical degree from Albany Medical College and has been in practice 27 years. She specializes in hematologic oncology and is experienced in mitral valve prolapse, amyloidosis, hematopoietic stem cell transplantation, bone marrow transplantation, and multiple myeloma. She has more than 100 publications and over 500 citings.

Education & Training

Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1993 - 1996
University of RochesterResidency, Internal Medicine, 1990 - 1993
Albany Medical CollegeClass of 1990

Certifications & Licensure

CA State Medical License 1996 - 2025
NY State Medical License 1991 - 1994
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Top Doctors:LA Area Castle Connolly, 2013

Clinical Trials

Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) Start of enrollment: 2003 Dec 01
Completed
Phase 3
Zevalin-beam for Aggressive Lymphoma Start of enrollment: 2007 Jun 01
Completed
Phase 3
Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma Start of enrollment: 2007 Jun 01
Completed
Phase 1
Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma Start of enrollment: 2000 May 10
Active, not recruiting
Phase 1
Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma Start of enrollment: 2008 Mar 18
Completed
Phase 2
Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma Start of enrollment: 2010 Apr 01
Completed
Phase 1
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Start of enrollment: 2010 May 01
Completed
Phase 3
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 Start of enrollment: 2010 Oct 01
Active, not recruiting
Phase 3
Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma Start of enrollment: 2015 Dec 31
Active, not recruiting
Phase 1
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Start of enrollment: 2014 Jun 30
Completed
Phase 1, Phase 2
A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies Start of enrollment: 2014 Aug 25
Terminated
Phase 1
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma Start of enrollment: 2016 Dec 01
Terminated
Phase 1
Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma Start of enrollment: 2018 Feb 21
Completed
Phase 1
Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma Start of enrollment: 2019 Jul 17
Active, not recruiting
Phase 2
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies Start of enrollment: 2018 Feb 22
Completed
Phase 1
Roles: Contact
Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia Start of enrollment: 2018 Oct 25
Withdrawn
Phase 1
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration Start of enrollment: 2019 Aug 13
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

1 citations
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Te...
Marcelo C Pasquini, Paul K Wallace, Brent Logan, Manmeet Kaur, Joseph D Tario
Journal of Clinical Oncology. 2024-08-10
79 citations
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.
Luciano J. Costa, Benjamin A. Derman, Susan Bal, Surbhi Sidana, Saurabh Chhabra
Leukemia. 2021-01-01
99 citations
A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteris...
Henry C. Fung, Anthony S. Stein, Marilyn L. Slovak, M R O'Donnell, David S. Snyder
Biology of Blood and Marrow Transplantation. 2003-12-01

Abstracts/Posters

Tandem Autologous-Autologous Vs. Autologous-Allogeneic Transplantation for Newly Diagnosed Multiple Myeloma: Pooled Analysis of 1,338 Patients from Four Trials with Lo...
Amrita Y. Krishnan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma
Amrita Y. Krishnan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Current Obstacles in Myeloma Management: Debating the Evidence
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
First-in-Human Imaging of Multiple Myeloma Using Copper-64-Labeled Daratumumab: Preliminary Results
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
CD84: A Potential Novel Therapeutic Target in Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: Final Analysis of a Phase 1 Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Split First Dose Administration of Daratumumab for the Treatment of Patients with Multiple Myeloma (MM): Clinical Pharmacology and Population Pharmacokinetic (PK) Anal...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A phase 1 open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-001, an anti-CD74 antibody drug conjugate, in patients with advanced B-cell malig...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Join now to see all

Press Mentions

FDA OKs Subcutaneous Daratumumab plus VRd for MyelomaJuly 31st, 2024
City of Hope O.C. Offers Sneak Peek at Coming Irvine Cancer HospitalMarch 28th, 2023
Multiple Myeloma Squad (Don’t Call It ‘Cancer Club’) Is on a Mission for LifeAugust 31st, 2021
Join now to see all